Kidney Cancer: December 2006 Archives

kidney cancerWyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has accepted the file and granted priority review status to the Company's New Drug Application (NDA) for the investigational drug Torisel(TM) (temsirolimus). Wyeth Pharmaceuticals is seeking an indication for Torisel for the treatment of advanced renal cell carcinoma (RCC). A priority designation can be given to an NDA for a drug that, if approved, would be a significant improvement compared with existing treatments.

The FDA previously granted fast track designation and orphan drug status for investigational temsirolimus for the treatment of advanced RCC.

About this Archive

This page is a archive of entries in the Kidney Cancer category from December 2006.

Kidney Cancer: November 2006 is the previous archive.

Kidney Cancer: January 2007 is the next archive.

Find recent content on the main index or look in the archives to find all content.